Plecanatide Levels and Effects while Breastfeeding
Summary of Use during Lactation
Plecanatide is not absorbed from the gastrointestinal tract and the drug and its active metabolite are not measurable in milk following administration of recommended doses to nursing mothers. Plecanatide is not expected to cause any adverse effects in breastfed infants. No special precautions are required.
Drug Levels
Maternal Levels. Plecanatide 3 mg was administered orally once daily for 2 weeks to 7 mothers who had been nursing for at least 4 weeks. Plecanatide and its active metabolite were not measurable (detection limit not specified) in breastmilk samples collected before a dose or at 2, 6, or 12 hours after a dose.[1,2]
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Bausch Health Americas Inc. A postmarketing study of plecanatide in breast milk of lactating women treated with Trulance. Clinical Trials.gov 2018:NCT03551873. https://clinicaltrials.gov/ct2/show/NCT03551873?term=NCT03551873&draw=2&rank=1
2.
Salix Pharmaceuticals Inc. Trulance Package Insert. 2020
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
